Study of treatment for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called HER2-negative adenocarcinoma that hasn't spread to other organs.
- You are between 18 and 80 years old and able to do most daily activities without help.
- You have not had any chemotherapy, radiation, or other cancer treatment for this cancer yet.
- Your blood counts and liver/kidney function must be within a certain healthy range.
- You don't have any other serious health problems like uncontrolled heart disease, active infections, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This study tests a combination of two treatments for stomach cancer that has spread to the lining of the belly. It uses an immunotherapy drug (tislelizumab) plus standard chemotherapy (SOX) and a heated chemotherapy treatment directly into the belly (HIPEC) to see if this approach is safe and effective.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
Hear when a new Gastric Cancer, Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.